Beneficial treatment of age-related sleep disturbances with prolonged intranasal vasopressin

Journal of Clinical Psychopharmacology

Volumn 19, Issue 1, 1999, Pages 28-36

  Perras, Boris ^a   Pannenborg, Hagen ^a   Marshall, Lisa ^a   Pietrowsky, Reinhard ^a,b   Born, Jan ^a,b   Fehm, Horst Lorenz ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b UNIVERSITY OF BAMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARGIPRESSIN; HYDROCORTISONE; VASOPRESSIN;

AGING; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; INTRANASAL DRUG ADMINISTRATION; LONG TERM CARE; MALE; NIGHT SLEEP; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REM SLEEP; SLEEP DISORDER; SLEEP TIME; SLOW WAVE SLEEP; SYSTOLIC BLOOD PRESSURE;

ADMINISTRATION, INHALATION; AGED; AGED, 80 AND OVER; AGING; BLOOD CELL COUNT; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; DOUBLE-BLIND METHOD; ENDOCRINE SYSTEM; FEMALE; HEART RATE; HUMANS; LEARNING; MALE; SLEEP DISORDERS; SLEEP, REM; VASOPRESSINS;

EID: 0032908509     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199902000-00007     Document Type: Article

References (53)

1. Weindl a, Sofroniew M. Neuroanatomical pathways related to vasopressin. In: Ganten D, Pfaff D, eds. Current topics in neuroendocrinology. Berlin: Springer, 1985:137-96.
2. Van Wimersma Greidanus TB, Burbach JP, Veldhuis HD. Vasopressin and oxytocin: their presence in the central nervous system and their functional significance in brain processes related to behaviour and memory. Acta Endocrinol Suppl (Copenh) 1986;276:85-94.
3. Philips PA, Abrahams JM, Kelly JM, Mooser M, Trinder D, Johnston CI. Localization of vasopressin binding sites in rat tissue using specific V1 and V2 selective ligands. Endocrinology 1990;126:1478-84.
4. Loup F, Tribollet E, Dubois-Dauphin M, Dreifuss JJ. Localization of high-affinity binding sites for oxytocin and vasopressin in the human brain: an autoradiographic study. Brain Res 1991;555: 220-32.
5. Swaab DF, Fliers E, van Gool WA. Immunocytochemical localization of vasopressin in the human brain: its possible consequences for therapeutic strategies in aging and dementia. Prog Brain Res 1986;65:105-13.
6. Swaab DF. Ageing of the human hypothalamus. Horm Res 1995;43:8-11.
7. Hofman MA, Swaab DF. Alterations in circadian rhythmicity of the vasopressin producing neurons of the human suprachiasmatic nucleus (SCN) with aging. Brain Res 1994;651:134-42.
8. Klein DC, Moore RY, Reppert SM. Suprachiasmatic nucleus: the mind's clock. New York: Oxford University Press, 1991.
9. De Wied D. The influence of the posterior and intermediate lobe of the pituitary and pituitary peptides on the maintenance of a conditioned avoidance response in rats. Int J Neuropharmacol 1965;4:157-67.
10. Van Wimersma Greidanus TB, Van Ree JM. Behavioral effects of vasopressin. In: Ganten D, Pfaff D, eds. Behavioral aspects of neuroendocrinology. Berlin: Springer, 1990:61-79.
11. Nebes RD, Reynolds CF, Horn LC. The effect of vasopressin on memory in the healthy elderly. Psychiatr Res 1984;11:49-59.
12. Fehm-Wolfsdorf G, Born J. Behavioral effects of neurohypophyseal peptides in healthy volunteers: 10 years of research. Peptides 1991;12:1399-406.
13. Dodt C, Pietrowsky R, Sewing A, Zabel A, Fehm HL, Born J. Effects of vasopressin on event-related potential indicators of cognitive stimulus processing in young and old humans. J Gerontol 1994;49:M183-8.
14. Perras B, Mölle M, Born J, Fehm HL. Sleep and signs of attention during 3 month of intranasal vasopressin: a pilot study in two elderly subjects. Peptides 1996;17:1253-5.
15. Born J, Fehm-Wolfsdorf G, Lutzenberger W, Voigt KH, Fehm HL. Vasopressin and electrophysiological signs of attention in man. Peptides 1986;7:189-93.
16. Fehm-Wolfsdorf G, Bacholz G, Born J, Voigt KH, Fehm HL. Vasopressin but not oxytocin enhances cortical arousal: an integrative hypothesis on behavioral effects of neurohypophyseal hormones. Psychopharmacology (Berl) 1988;94:496-500.
17. Gottlieb GL. Sleep disorders and their management: special considerations in the elderly. Am J Med 1990;88(3A):29S-33S.
18. Prinz PN, Vitiello MV, Raskind MA, Thorpy MJ. Geriatrics: sleep disorders and aging. N Engl J Med 1990;323:520-6.
19. Weitzman ED, Zimmerman JC, Czeisler CA, Ronda J. Cortisol secretion is inhibited during sleep in normal man. J Clin Endocrinol Metab 1983;56:352-8.
20. Born J, Muth S, Fehm HL. The significance of sleep onset and slow wave sleep for nocturnal release of growth hormone (GH) and cortisol. Psychoneuroendocrinology 1988;13:233-43.
21. Prinz PN, Moe KE, Dulberg EM, Larsen LH, Vitiello MV, Toivola B, Merriam GR. Higher plasma IGF-1 levels are associated with increased delta sleep in healthy older men. J Gerontol Med Sci 1995;50A:M222-6.
22. Riekkinen P, Legros JJ, Sennef C, Jolkkonen J, Smitz S, Soininen H. Penetration of DGAVP (Org 5667) across the blood-brain barrier in human subjects. Peptides 1987;8:261-5.
23. Balin BJ, Broadwell RD, Salcman M, El-Kalliny M. Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey. J Comp Neurol 1986;251:260-80.
24. Itaya SK. Anterograde transsynaptic transport of WGA-HRP in rat olfactory pathways. Brain Res 1987;409:205-14.
25. Pietrowsky R, Strüben C, Mölle M, Fehm HL, Born J. Brain potential changes after intranasal vs. intravenous administration of vasopressin: evidence for a direct nose-brain pathway for peptide effects in humans. Biol Psychiatry 1996;39:332-40.
26. Rechtschaffen A, Kales A. A manual of standardized terminology, techniques and scoring system for sleep of human subjects [NIH publication no. 204]. Washington, DC: U.S. Government Printing Office, 1968.
27. Kales A, Wilson T, Kales JD, Jacobson A, Paulson MJ, Kollar E, Walter RD. Measurements of all-night sleep in normal elderly persons: effects of aging. J Am Geriatr Soc 1967;15:405-14.
28. Kahn E, Fisher C. The sleep characteristics of the normal aged male. J Nerv Ment Dis 1969;148:477-94.
29. Feinberg I. Changes in sleep cycle patterns with age. J Psychiatr Res 1974;10:283-306.
30. Webb WB. The measurement and characteristics of sleep in older persons. Neurobiol Aging 1982;3:311-9.
31. Ehlers CL, Kupfer DJ. Effects of age on delta and REM sleep parameters. Electroencephalogr Clin Neurophysiol 1989;72:118-25.
32. Cowley AW, Liard JF. Cardiovascular actions of vasopressin. In: Gash DM, Boer GJ, eds. Vasopressin: principles and properties. New York: Plenum Press, 1989:389-433.
33. Lamberts SWJ, Verleun T, Oosterom R, Dejong F, Hackeng WHL. Corticotropin-releasing factor (ovine) and vasopressin exert a synergistic effect on adrenocorticotropin release in man. J Clin Endocrinol Metab 1984;58:298-302.
34. Kellner M, Herzog L, Holsboer F, Wiedemann K. Circadian changes in the sensitivity of the corticotropin-releasing hormone-stimulated HPA system after arginine vasopressin and atrial natriuretic hormone in human male controls. Psychoneuroendocrinology 1995;20:515-24.
35. Born J, Zwick A, Roth G, Fehm-Wolfsdorf G, Fehm HL. Differential effects of hydrocortisone, fluocortolone, and aldosterone on nocturnal sleep in humans. Acta Endocrinol (Copenh) 1987;116: 129-37.
36. Born J, Späth-Schwalbe E, Schwakenhofer H, Kern W, Fehm HL. Influences of corticotropin-releasing hormone (CRH), adrenocorticotropin (ACTH), and cortisol on sleep in normal man. J Clin Endocrinol Metab 1989;68:904-11.
37. LeMoal M, Dantzer R, Mormede P, Baduel A, Lebrun C, Ettenberg A, van der Kooy D, Wenger J, Deyo S, Koob GF, Bloom FE. Behavioural effects of peripheral administration of arginine vasopressin: a review of our search for a mode of action and a hypothesis. Psychoneuroendocrinology 1984;9:319-41.
38. Zlokovic BV, Segal MB, Davson H, Lipovac MN, Hyman S, McComb JG. Circulating neuroactive peptides and the blood-brain and blood-cerebrospinal fluid barrier. Endocrinol Exp 1990;24:9-17.
39. Pietrowsky R, Thiemann A, Kern W, Fehm HL, Born J. A nose-brain pathway for psychotropic peptides: evidence from a brain evoked potential study with cholecystokinin. Psychoneuroendocrinology 1996;21:521-30.
40. Pietrowsky R, Born J, Kern W, Fehm HL. Functional evidence for a transmission of peptides along the olfactory systems into the brain in healthy humans. In: Krisch B, Mentlein R, eds. The peptidergic neuron. Basel: Birkhäuser, 1996:291-6.
41. Timsit-Berthier M, Mantanus H, Devos JE, Spiegel R. Action of lysin vasopressin on human electroencephalographic activity. Neuropsychobiology 1982;8:248-58.
42. Born J, Kellner C, Uthgenannt D, Kern W, Fehm HL. Vasopressin regulates human sleep by reducing rapid-eye-movement sleep. Am J Physiol 1992;262:E295-300.
43. Veldhuis D, De Kloet ER. Vasopressin-related peptides increase the hippocampal corticosterone receptor capacity of diabetes insipidus (Brattleboro) rats. Endocrinology 1982;110:153-7.
44. Born J, De Kloet ER, Wenz H, Kern W, Fehm HL. Gluco-and antimineralocorticoid effects on human sleep: a role of central corticosteroid receptors. Am J Physiol 1991;260:E183-8.
45. Friess E, von Bardeleben U, Wiedemann K, Lauer C, Holsboer F. Effects of pulsatile cortisol infusion on sleep-EEG and nocturnal growth hormone release in healthy men. J Sleep Res 1994; 3:73-9.
46. Wiedemann K, Lauer C, Loycke A, Pollmächer T, Durst P, Macher JP, Holsboer F. Antiglucocorticoid treatment disrupts endocrine cycle and nocturnal sleep pattern. Eur Arch Psychiatry Clin Neurosci 1992;241:372-5.
47. Fliers E, Swaab DF, Pool CW, Verwer RWH. The vasopressin and oxytocin neurons in the human supraoptic and paraventricular nucleus: changes with aging and in senile dementia. Brain Res 1985;342:45-53.
48. Van der Woude PF, Goudsmit E, Wierda M, Purba JS, Hofman MA, Bogte H, Swaab DF. No vasopressin cell loss in the human hypothalamus in aging and Alzheimer's disease. Neurobiol Aging 1995;16:11-8.
49. Shibata S, Moore RY. Neuropeptide Y and vasopressin effects on rat suprachiasmatic nucleus neurons in vitro. J Biol Rhythms 1988;3:265-76.
50. Czeisler CA, Dumont M, Duffy JF, Steinberg JD, Richardson GS, Brown EN, Sanchez R, Rios CD, Ronda JM. Association of sleepwake habits in older people with changes in output of circadian pacemaker. Lancet 1992;340:933-6.
51. Carskadon MA, Dement WC, Mitler MM, Guilleminault C, Zarcone VP, Spiegel R. Self-reports versus sleep laboratory findings in 122 drug-free subjects with complaints of chronic insomnia. Am J Psychiatry 1976;133:1382-3.
52. Mendelson WB, Garnett D, Gillin JC, Weingartner H. The experience of insomnia and daytime and nighttime functioning. Psychiatry Res 1984;12:235-50.
53. Mendelson WB, James SP, Garnett D, Sack DA, Rosenthal NE. A psychophysiological study of insomnia. Psychiatry Res 1986;19: 267-84.